Study Title: NIV001
NIV001: A phase I safety and immunogenicity trial of a Nipah virus vaccine, ChAdOx1 NipahB, in healthy volunteers aged 18-55 years in the UK
LEGACY03: Lymph node flu & COVID-19 vaccine responses in younger or older adults
You are invited to take part in a study examining lymph nodes cells to assess immune responses in younger and older adults after immunisation with seasonal influenza vaccine and mRNA COVID-19 vaccine boosters. The study is being led by the Oxford Vaccine Group, which is part of the University of Oxford, and is taking place at the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill Hospital.
Recruiting now for The 6-in-1 Part 2 Vaccine Study. Oxford Vaccine Group, University of Oxford would like to invite your child to take part in a study to help guide future changes to the UK immunisation schedule. We want to enroll healthy children, who have not yet received their 12-month routine vaccinations.
You are invited to take part in a challenge study to investigate whether a novel vaccine can prevent malaria. The study is being run by the Oxford Vaccine Group in partnership with the Department of Biochemistry which is part of the University of Oxford and is funded by PATH.
You are invited to take part in a study to investigate a new vaccine for Crimean-Congo haemorrhagic fever virus. The study is being led by the Oxford Vaccine Group, which is part of the University of Oxford, and is taking place at the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill Hospital.
We are looking for healthy volunteers aged 18 – 30 years old to take part in a new COVID-19 Human Challenge Study.
In this study, we are trying to find out how we can best protect people against pertussis (more commonly known as whooping cough). Pertussis is a highly contagious infection of the lungs and airways, caused by bacteria (small organisms which can reproduce and cause illness) called Bordetella pertussis (B. pertussis). The groups of people most severely affected by pertussis are babies, the elderly, people with chronic medical conditions that affect the lungs and heart, and people who are immunocompromised (unable to respond normally to an infection).
Join our vaccine study and help us beat paratyphoid together!
The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.